Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor

Blood

Volumn 115, Issue 5, 2010, Pages 1037-1048

  Pecquet, Christian ^a,b   Staerk, Judith ^a,b   Chaligne, Ronan ^c   Goss, Valerie ^d   Lee, Kimberly A ^d   Zhang, Xiaowu ^d   Rush, John ^d   Van Hees, Joanne ^a,b   Poirel, Hélène A ^b,e   Scheiff, Jean Marie ^e   Vainchenker, William ^c   Giraudier, Stéphane ^c   Polakiewicz, Roberto D ^d   Constantinescu, Stefan N ^a,b,f  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^b DE DUVE INSTITUTE   (Belgium)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d CELL SIGNALING TECHNOLOGY   (United States)

^e CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^f UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; PHENYLALANINE; PHOSPHOTYROSINE; THROMBOPOIETIN RECEPTOR; THROMBOPOIETIN RECEPTOR W515; TYROSINE 112; TYROSINE DERIVATIVE; UNCLASSIFIED DRUG; PHOSPHOPROTEIN; TYROSINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW; CONTROLLED STUDY; DNA FLANKING REGION; ENZYME ACTIVATION; GENE DELETION; GENE MUTATION; HUMAN; IN VIVO STUDY; MOUSE; MUTANT; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; ANIMAL; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CELL LINE; CELL PROLIFERATION; CYTOLOGY; GENETIC TRANSFECTION; GENETICS; IMMUNOBLOTTING; METABOLISM; MUTATION; MYELOID METAPLASIA; PATHOLOGY; PHOSPHORYLATION; PRE B LYMPHOCYTE;

ANIMALS; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CELL LINE; CELL PROLIFERATION; HUMANS; IMMUNOBLOTTING; JANUS KINASE 2; MICE; MUTATION; MYELOPROLIFERATIVE DISORDERS; PHOSPHOPROTEINS; PHOSPHORYLATION; PRECURSOR CELLS, B-LYMPHOID; PRIMARY MYELOFIBROSIS; RECEPTORS, THROMBOPOIETIN; TRANSFECTION; TYROSINE;

EID: 77649208164     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-10-183558     Document Type: Article

References (67)

1. Wendling F, Maraskovsky E, Debili N, et al. cMpl ligand is a humoral regulator of megakaryocytopoiesis. Nature. 1994;369(6481):571-574. (Pubitemid 2089104)
2. de Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature. 1994;369(6481):533-538. (Pubitemid 24192520)
3. Kaushansky K, Lok S, Holly RD, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature. 1994;369(6481):568-571. (Pubitemid 24192526)
4. Gurney AL, Carver-Moore K, de Sauvage FJ, Moore MW. Thrombocytopenia in c-mpl-deficient mice. Science. 1994;265(5177):1445-1447.
5. Alexander WS, Roberts AW, Nicola NA, Li R, Metcalf D. Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl. Blood. 1996;87(6):2162-2170. (Pubitemid 26086854)
6. de Sauvage FJ, Carver-Moore K, Luoh SM, et al. Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med. 1996;183(2):651-656. (Pubitemid 26059523)
7. Solar GP, Kerr WG, Zeigler FC, et al. Role of c-mpl in early hematopoiesis. Blood. 1998;92(1):4-10.
8. Abkowitz JL, Chen J. Studies of c-Mpl function distinguish the replication of hematopoietic stem cells from the expansion of differentiating clones. Blood. 2007;109(12):5186-5190. (Pubitemid 46890535)
9. Yoshihara H, Arai F, Hosokawa K, et al. Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. Cell Stem Cell. 2007;1(6):685-697. (Pubitemid 350215333)
10. Qian H, Buza-Vidas N, Hyland CD, et al. Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells. Cell Stem Cell. 2007;1(6):671-684. (Pubitemid 350215331)
11. Miyakawa Y, Oda A, Druker BJ, et al. Recombinant thrombopoietin induces rapid protein tyrosine phosphorylation of Janus kinase 2 and Shc in human blood platelets. Blood. 1995;86(1):23-27.
12. Sattler M, Durstin MA, Frank DA, et al. The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases. Exp Hematol. 1995;23(9):1040-1048.
13. Drachman JG, Millett KM, Kaushansky K. Thrombopoietin signal transduction requires functional JAK2, not TYK2. J Biol Chem. 1999;274(19):13480-13484. (Pubitemid 129518562)
14. Royer Y, Staerk J, Costuleanu M, Courtoy PJ, Constantinescu SN. Janus kinases affect thrombopoietin receptor cell surface localization and stability. J Biol Chem. 2005;280(29):27251-27261. (Pubitemid 41040765)
15. Alexander WS, Metcalf D, Dunn AR. Point mutations within a dimer interface homology domain of c-Mpl induce constitutive receptor activity and tumorigenicity. EMBO J. 1995;14(22):5569-5578.
16. Remy I, Wilson IA, Michnick SW. Erythropoietin receptor activation by a ligand-induced conformation change. Science. 1999;283(5404):990-993. (Pubitemid 129505219)
17. Constantinescu SN, Huang LJ, Nam H, Lodish HF. The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif. Mol Cell. 2001;7(2):377-385. (Pubitemid 32206505)
18. Drachman JG, Kaushansky K. Dissecting the thrombopoietin receptor: functional elements of the Mpl cytoplasmic domain. Proc Natl Acad Sci U S A. 1997;94(6):2350-2355. (Pubitemid 27136878)
19. Gaur M, Murphy GJ, deSauvage FJ, Leavitt AD. Characterization of Mpl mutants using primary megakaryocyte-lineage cells from mpl(-/-) mice: a new system for Mpl structure-function studies. Blood. 2001;97(6):1653-1661. (Pubitemid 32217230)
20. Gurney AL, Wong SC, Henzel WJ, de Sauvage FJ. Distinct regions of c-Mpl cytoplasmic domain are coupled to the JAK-STAT signal transduction pathway and Shc phosphorylation. Proc Natl Acad Sci U S A. 1995;92(12):5292-5296.
21. Alexander WS, Maurer AB, Novak U, Harrison-Smith M. Tyrosine-599 of the c-Mpl receptor is required for Shc phosphorylation and the induction of cellular differentiation. EMBO J. 1996;15(23):6531-6540. (Pubitemid 26413786)
22. Miyakawa Y, Rojnuckarin P, Habib T, Kaushansky K. Thrombopoietin induces phosphoinositol 3-kinase activation through SHP2, Gab, and insulin receptor substrate proteins in BAF3 cells and primary murine megakaryocytes. J Biol Chem. 2001;276(4):2494-2502. (Pubitemid 37376620)
23. Kubatzky KF, Liu W, Goldgraben K, Simmerling C, Smith SO, Constantinescu SN. Structural requirements of the extracellular to transmembrane domain junction for erythropoietin receptor function. J Biol Chem. 2005;280(15):14844- 14854. (Pubitemid 40562834)
24. Lu X, Gross AW, Lodish HF. Active conformation of the erythropoietin receptor: random and cysteine-scanning mutagenesis of the extracellular juxtamembrane and transmembrane domains. J Biol Chem. 2006;281(11):7002-7011. (Pubitemid 43847463)
25. Staerk J, Lacout C, Smith SO, Vainchenker W, Constantinescu SN. An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. Blood. 2006;107:1864-1871. (Pubitemid 43289364)
26. Constantinescu SN, Keren T, Socolovsky M, Nam H, Henis YI, Lodish HF. Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain. Proc Natl Acad Sci U S A. 2001;98(8):4379-4384. (Pubitemid 32294985)
27. Seubert N, Royer Y, Staerk J, et al. Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer. Mol Cell. 2003;12(5):1239-1250. (Pubitemid 37487931)
28. Brown RJ, Adams JJ, Pelekanos RA, et al. Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat Struct Mol Biol. 2005;12(9):814-821.
29. Remy I, Wilson IA, Michnick SW. Erythropoietin receptor activation by a ligand-induced conformation change. Science. 1999;283:990-993. (Pubitemid 129505219)
30. Huang LJ, Constantinescu SN, Lodish HF. The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. Mol Cell. 2001;8(6):1327-1338.
31. Pikman Y, Lee BH, Mercher T, et al. MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia. PLoS Med. (http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed. 0030270) 2006;3(7):e270.
32. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108(10):3472-3476.
33. Marty C, Chaligne R, Lacout C, Constantinescu SN, VainchenkerW, Villeval JL. Ligand-independent thrombopoietin mutant receptor requires cell surface localization for endogenous activity. J Biol Chem. 2009;284(18):11781-11791.
34. Luoh SM, Stefanich E, Solar G, et al. Role of the distal half of the c-Mpl intracellular domain in control of platelet production by thrombopoietin in vivo. Mol Cell Biol. 2000;20(2):507-515. (Pubitemid 30023092)
35. Chaligné R, Tonetti C, Besancenot R, et al. New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G(1)/Sphase transition. Leukemia. 2008;22(8):1557-1566.
36. Liu X, Constantinescu SN, Sun Y, et al. Generation of mammalian cells stably expressing multiple genes at predetermined levels. Anal Biochem. 2000;280(1):20-28. (Pubitemid 30210807)
37. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-1148. (Pubitemid 40663494)
38. Chagraoui H, Komura E, Tulliez M, Giraudier S, Vainchenker W, Wendling F. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood. 2002;100(10):3495-3503. (Pubitemid 35303916)
39. Walters DK, Mercher T, Gu TL, et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell. 2006;10(1):65-75.
40. Abe M, Suzuki K, Inagaki O, Sassa S, Shikama H. A novel MPL point mutation resulting in thrombopoietin-independent activation. Leukemia. 2002;16(8):1500-1506.
41. Rush J, Moritz A, Lee KA, et al. Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol. 2005;23(1):94-101. (Pubitemid 41724631)
42. Goss VL, Lee KA, Moritz A, et al. A common phosphotyrosine signature for the Bcr-Abl kinase. Blood. 2006;107(12):4888-4897. (Pubitemid 43882642)
43. Palacios R, Steinmetz M. Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell. 1985;41(3):727-734.
44. Feng J, Witthuhn BA, Matsuda T, Kohlhuber F, Kerr IM, Ihle JN. Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. Mol Cell Biol. 1997;17(5):2497-2501. (Pubitemid 27175130)
45. Schnittger S, Bacher U, Haferlach C, et al. Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis. Haematologica. 2009;94(1):141-144.
46. Hitchcock IS, Chen MM, King JR, Kaushansky K. YRRL motifs in the cytoplasmic domain of the thrombopoietin receptor regulate receptor internalization and degradation. Blood. 2008;112(6):2222-2231.
47. Fink AL. Natively unfolded proteins. Curr Opin Struct Biol. 2005;15(1):35-41.
48. Fersht AR. From the first protein structures to our current knowledge of protein folding: delights and scepticisms. Nat Rev Mol Cell Biol. 2008;9(8):650-654.
49. Radtke S, Hermanns HM, Haan C, et al. Novel role for Janus kinase 1 in the regulation of oncostatin M receptor surface expression. J Biol Chem. 2002;277(13):11297-11305.
50. Ragimbeau J, Dondi E, Alcover A, Eid P, Uze G, Pellegrini S. The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression. EMBO J. 2003;22(3):537-547. (Pubitemid 36193598)
51. Chaligné R, James C, Tonetti C, et al. Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis. Blood. 2007; 110(10):3735-3743. (Pubitemid 350159644)
52. Jamieson CH, Gotlib J, Durocher JA, et al. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci U S A. 2006;103(16):6224-6229.
53. Lacout C, Pisani DF, Tulliez M, Moreau Gachelin F, Vainchenker W, Villeval JL. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood. 2006;108(5):1652-1660. (Pubitemid 44316134)
54. Bumm TG, Elsea C, Corbin AS, et al. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res. 2006;66(23):11156- 11165. (Pubitemid 46009942)
55. Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood. 2006;107(11):4274-4281. (Pubitemid 43801351)
56. Zaleskas VM, Krause DS, Lazarides K, et al. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS ONE. (http:www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0000018) 2006;1:e18.
57. Onishi M, Mui AL, Morikawa Y, et al. Identification of an oncogenic form of the thrombopoietin receptor MPL using retrovirus-mediated gene transfer. Blood. 1996;88(4):1399-1406. (Pubitemid 26276816)
58. Ding J, Komatsu H, Wakita A, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood. 2004;103(11):4198-4200. (Pubitemid 38685363)
59. Malinge S, Ragu C, Della-Valle V, et al. Activating mutations in human acute megakaryoblastic leukemia. Blood. 2008;112(10):4220-4226.
60. Pardanani A, Hood J, Lasho T, et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia. 2007;21(8):1658-1668. (Pubitemid 47086756)
61. Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia. 2008;22(1):23-30.
62. Gozgit JM, Bebernitz G, Patil P, et al. Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2. J Biol Chem. 2008;283(47):32334-32343.
63. Knoops L, Diaconu CC, Constantinescu SN. Using Jak2 inhibitors in myeloproliferative neoplasms. Myeloproliferative Disord Pract. 2008;2(1):3-6.
64. Geron I, Abrahamsson AE, Barroga CF, et al. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell. 2008;13(4):321-330.
65. Wernig G, Kharas MG, Okabe R, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell. 2008;13(4):311-320.
66. Villeval JL, Cohen-Solal K, Tulliez M, et al. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood. 1997;90(11):4369-4383. (Pubitemid 27508443)
67. Kaushansky K. Etiology of the myeloproliferative disorders: the role of thrombopoietin. Semin Hematol. 2003;40(1 suppl 1):6-9. (Pubitemid 36403117)